F S&P 500
5,331.50 -0.25 (-0.00%) F Dow Jones
39,943.00 -1.00 (-0.00%) F Nasdaq
18,745.00 -18.00 (-0.10%) E-mini Russell 2000 Index Futur
2,106.10 -3.80 (-0.18%) Petróleo
78.73 -1.07 (-1.34%) Oro
2,420.00 -18.50 (-0.76%)
OncoCyte Corporation (OCX)
OncoCyte Corporation
15 Cushing
Irvine, CA 92618
United States
949 409 7600
https://www.oncocyte.com
Sector(es): Healthcare
Industria: Diagnostics & Research
Empleados a tiempo completo: 43
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Joshua Riggs | President, CEO & Director | 504.63k | N/D | 1983 |
| Mr. James Liu | Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer | 259.83k | N/D | 1996 |
| Dr. Ekkehard Schutz M.D., Ph.D. | Chief Science Officer | 409.27k | N/D | N/D |
| Mr. Peter Hong | VP, General Counsel & Secretary | N/D | N/D | N/D |
| Mr. Yuh-Min Chiang Ph.D. | Senior Vice President of R&D and Product Development | N/D | N/D | N/D |
| Ms. Sandra O'Donald | Senior Vice President of Business Operations | N/D | N/D | N/D |
| Dr. Michael D. West Ph.D. | Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. | N/D | N/D | 1953 |
Descripción
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Gestión corporativa
La calificación ISS Governance QuickScore de OncoCyte Corporation a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
